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Abstract
There is a growing literature on the impact of genetic variation on outcome in traumatic brain injury (TBI). Whereas a
substantial proportion of these publications have focused on the apolipoprotein E (APOE) gene, several have explored the
influence of other polymorphisms.We undertook a systematic review of the impact of single-nucleotide polymorphisms (SNPs)
in non–apolipoprotein E (non-APOE) genes associated with patient outcomes in adult TBI). We searched EMBASE, MED-
LINE, CINAHL, and gray literature from inception to the beginning ofAugust 2017 for studies of genetic variance in relation to
patient outcomes in adult TBI. Sixty-eight articles were deemed eligible for inclusion into the systematic review. The SNPs
described were in the following categories: neurotransmitter (NT) in 23, cytokine in nine, brain-derived neurotrophic factor
(BDNF) in 12, mitochondrial genes in three, and miscellaneous SNPs in 21. All studies were based on small patient cohorts
and suffered from potential bias. A range of SNPs associated with genes coding for monoamine NTs, BDNF, cytokines, and
mitochondrial proteins have been reported to be associatedwith variation in global, neuropsychiatric, and behavioral outcomes.
An analysis of the tissue, cellular, and subcellular location of the genes that harbored the SNPs studied showed that they could be
clustered into blood–brain barrier associated, neuroprotective/regulatory, and neuropsychiatric/degenerative groups. Several
small studies report that variousNT, cytokine, andBDNF-related SNPs are associatedwith variations in global outcome at 6–12
months post-TBI. The association of these SNPs with neuropsychiatric and behavioral outcomes is less clear. A definitive
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assessment of role and effect size of genetic variation in these genes on outcome remains uncertain, but could be clarified by an
adequately powered genome-wide association study with appropriate recording of outcomes.
Keywords: genetics; living systematic review; outcome; prognosis; traumatic brain injury
Introduction
Outcome prediction in severe traumatic brain injury (TBI) canbe improved. Numerous research groups have produced prog-
nostic models in an effort to predict outcome based on acute-phase
patient demographics and clinical parameters.1–3 The International
Mission for Prognosis and Clinical Trials in Traumatic Brain Injury
(IMPACT) model is a typical (and probably the best known) exem-
plar of such a prognostic model.1–3 However, none of the available
prognostic models include genetic variation as a variable.
Current implementations of the IMPACT model can predict
outcome with an area under the receiver operating curve between
0.60 and 0.80,1,3 with partial R2 values that approach 0.35, sug-
gesting that well over half of the variance in outcome is not ac-
counted for by injury severity or type, age, or physiological or
biochemical compromise immediately post-injury. This large un-
explained outcome variance suggests that there may be other po-
tential factors that contribute to outcome.4
One key contributor in this context may be genetic variation,
which could impact outcome by modulating pre-injury reserve,
secondary injury mechanisms, neural repair, and/or the activation
of neurodegenerative processes.5 The largest body of literature
in this context focuses on the impact of genetic variations in
apolipoprotein-E (APOE) on patient outcome post-TBI and pro-
vides evidence of a potentially significant, but inconsistent, impact
of APOE polymorphisms on outcome.7,8,10,11 Whereas these rela-
tionships are interesting and relevant, they do not form the focus of
this systematic review. APOE polymorphisms will be covered in
a separate living systematic review by our group.
We chose instead, in this article, to focus on single-nucleotide
polymorphisms (SNPs) in genes other than those related to APOE,
which have also been reported to have an impact on patient out-
come. Although this body of literature is substantial and steadily
growing, it has never been subjected to rigorous review, and no
single publication provides a comprehensive summary of the
available data in this area. Thus, the goal of this article is to provide
a rigorous assessment of studies reporting the impact of non-APOE
SNPs on patient outcome post-TBI. Given the continuing accu-
mulation of new studies on this topic, this article is designed to be
a living systematic review,12 with periodic updates on the available
literature to be published as new evidence becomes available. The
question of interest for this systematic review was: What non-
APOE SNPs are associated with patient outcome post-TBI?
Methods
This review was conducted and reported in line with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Statement.13 A protocol was registered on June 10,
2014 with the University of York’s International Prospective
Register of Systematic Reviews (PROSPERO) database (registration
number CRD42014013623; available at: http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42014013623).
This review is being prepared as a ‘‘living systematic review’’ as
part of the CENTER-TBI project (www.center-tbi.eu).14 A living
systematic review is a high-quality, up-to-date online summary of
health research that is updated as new research becomes avail-
able.12 In practice, this means that the searches will be rerun fre-
quently and any new studies incorporated into the review. We will
seek to publish regular updates. In this context, we would see this
article as part of a knowledge commons, which would provide a
basis for ongoing update of the available literature in this area,
could be revised and updated by collaboration between both current
and new contributors.
Inclusion/exclusion criteria
We included all studies of five or more adult patients (over 16
years of age) with TBI of all severities, which reported a global
functional outcome measure of any type, reported by patient ge-
notype (including mortality, Glasgow Outcome Scale [GOS],
GOS-extended [GOSE], and Disability Rating Scale [DRS]). We
also included studies that reported neuropsychological outcome.
We only included studies in the English language.
We excluded studies that included non-TBI or pediatric patients,
and those that did not report outcome data separately for the adult
TBI cohort. Studies reporting nonfunctional outcome measures, such
as histological findings at post-mortem, were also excluded. We
elected to exclude studies with less than 5 patients given that such
small patient numbers would not likely add to our review. Con-
versely, we did not restrict ourselves only to studies with a larger
number of patients because this would have excluded several of the
publications in this field. Finally, any studies reporting APOE as the
genetic association of interest were not included within this sys-
tematic review.A separate living systematic review onAPOE, and its
association with patient outcome in adult TBI, is currently underway
by our group. This was conducted as a separate living systematic
review given the large volume of APOE studies available, war-
ranting a separate review dedicated to this gene in adult TBI.
Search strategy
At the beginning of August 2017, EMBASE, MEDLINE, and
CINAHL (all through National Institute for Health and Clinical
Excellence [NICE] Healthcare Databases) andGoogle Scholar were
searched for published studies, and conference abstracts from in-
ception to the start of August 2017 inclusive. Developed with search
experts at Monash University’s National Trauma Research Institute
(NTRI), search strategies used a combination of keywords and
MeSH terms (see Supplementary Appendix 1). Reference lists of
included studies were manually reviewed to identify relevant pub-
lications not identified by the search strategy. Wherever conference
abstracts were found, a further PubMed search was performed to
discover whether the data had subsequently been published in full.
Editor’s Note: This article is published as a Living Systematic
Review. All Living Systematic Reviews will be updated at
approximately three-six month intervals, with these updates
published as supplementary material in the online version of
the Journal of Neurotrauma.
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Study selection
Citations were downloaded into EndNote (Thomson Reuters)
and duplicates removed. Titles and abstracts were screened against
the eligibility criteria in EndNote by one author (C.A.M.), to re-
move irrelevant studies, and the remaining citations were reviewed
in full text independently by two authors (C.A.M., with either
V.F.J.N. or F.A.Z.) to assess them for eligibility. Disagreements
regarding eligibility were resolved by consensus, and referral to a
third reviewer (D.K.M.) was not required.
Data extraction
Citations and full-text files for all included studies were up-
loaded to Covidence (www.covidence.org), an online systematic
review workflow tool, to undertake quality assessment and data
extraction. Two authors (C.A.M., with either F.A.Z. or V.F.J.N.)
independently extracted data, resolving disagreements through
consensus. The following characteristics were extracted from all
studies, where available:
1. Inclusion/exclusion criteria
2. Baseline characteristics, where possible, for each geno-
type within the cohort:
a. Cohort sex composition
b. Age (mean – standard deviation [SD] if available)
c. TBI severity (wherever possible as mean Glasgow Coma
Sclae [GCS] –SD, or GCS grouped according to existing
practice as mild, moderate, or severe TBI)
3. Outcome data (see below)
4. Funding source(s)
For studies reporting global functional outcomes (e.g., GOS/
GOSE, modified Rankin, numerical rating scale [NRS], DRS, and
mortality), scores were extracted at all available time points for
each genotype. Where possible, the total numbers of patients assessed
at each time point was extracted and used to calculate the number
of patients with a ‘‘favorable’’ outcome. Categorical scales were di-
chotomized in line with previously recognized methods for defining
‘‘favorable’’ outcomes (i.e., GOS 4–5, GOSE 5–8). If the reported
data simply included author-defined favorable or unfavorable out-
comes, without a breakdown of the underlying raw categorical data,
then this was extracted instead. If ordinal data were not available, the
mean scores and SDs (or standard errors/95% confidence intervals
[CIs]) were extracted. In studies dealing with neuropsychological
scales or other outcomes (e.g., measures of fatigue), reports of sta-
tistically significant differences between genotype results (at the alpha
level selected by the study’s authors) were extracted, with a narrative
notemade of nonsignificant results. In the case of no significant results
being reported, results of the study were assumed to show no positive
results, and the studywas reported as negative for the SNP in question.
Risk of bias assessment
Risk of bias was assessed using the Quality In Prognostic Studies
(QuIPS) risk of bias criteria, a validated domain-based tool for quality
assessment of prognostic studies.15 QuIPS addresses six important
areas to consider when evaluating validity and bias in studies of
prognostic factors: participation, attrition, prognostic factor mea-
surement, confounding measurement and account, outcome mea-
surement, and analysis and reporting. The rating system for QuIPs is
trichotomous, with a range from low risk, medium risk and high risk
of bias. The lowest risk of bias that a study may receive in any given
category is low risk. Two authors (C.A.M., with either F.A.Z. or
V.F.J.N.) independently completed theQuIPS for each study and then
reached a final judgement on each of the six domains by consensus.
The results of this process are presented for each study, as well as
tabulated for the study overall (Supplementary Appendix 11). In line
with the guidance provided by the team who developed QuIPS, we
did not calculate a summated score for overall study quality.
Data synthesis
Many of the publications reviewed included results on outcome
association for more than one SNP, and individual cohorts were
sometimes used to explore the effect of more than one SNP in sep-
arate publications, though this was not always explicitly stated.
Consequently, the results in the text of this article primarily relates to
analysis with references to specific SNPs. The tables in the Supple-
mentary Materials tabulate individual publications under summaries
for each SNP, or class of SNPs. Where a study was used to explore
more than one SNP or class of SNP, it was cited separately in the
table that addressed results for that SNP. Studies were grouped by
gene, where multiple mutations within a gene were studied. Within
each group of genes, studies were subdivided for analysis by TBI
severity/patient characteristics, or by outcome measures. Given the
large number of heterogeneous studies with mixed patient cohorts
and varied SNPs analyzed, a meta-analysis was not performed, and
the results were synthesized narratively. Simple descriptive statistics
can be found in the summary of patient cohorts for the various SNPs
analyzed (Supplementary Appendix 4).
Results
Search results
A total of 4549 citations were identified through database sear-
ches (Fig. 1). After removing duplicates, 4429 were screened on
citation and abstract, with 4166 excluded. We obtained 263 cita-
tions in full text, of which 105 were excluded (along with 92 review
articles). Two articles were added from the reference sections of the
included articles. The reasons for exclusion included non-TBI
study populations and ineligible outcome measures (see Supple-
mentary Appendix 3).
Patient and study demographics
We included 68 publications, reporting on the outcome impact
of SNPs in over 10,000 patients.16–29 It is difficult to be certain of
the actual number of individual patients included in these studies,
given that many originated from a small number of centers that
published several articles on different SNPs in possibly identical, or
at least overlapping, patient populations. Thus, the number of pa-
tients quoted across all of the studies is likely to be inflated sec-
ondary to counting individual patients more than once across the
various studies described. The true number of unique individual
patients studied across all of the included articles is likely sub-
stantially smaller. These 68 publications that described the out-
come impact of various SNPs, including 23 on neurotransmitter
(NT) SNPs,16–36,74,75 nine on cytokine SNPs.37–45 12 on brain-
derived neurotrophic factor (BDNF) SNPs,46–53,76–79 and three
articles on mitochondrial polymorphisms and patient outcome.54–55
A further 21 studies reported on varied miscellaneous SNPs that did
not fall into any of the previous groupings.57–73,80–83
Study design varied. Fifty-four publications described prospective
cohort studies16,17,19–24,26–31,34,35,37,38,40–44,46–53,55,57–64,66–69,71,73–80,83
Fourteen studies were retrospective cohort studies on banked DNA
samples18,25,32,33,36,39,45,54,56,65,70,72,82,83 Study location also varied
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significantly, with the most commonly reported country of origin
being the United States (n=43). Twenty-six studies included fewer
than 100 patients17,19,24,26,27,32,35,37,40,42–44,47,50–53,57,67–69,71,74,76,78,80
Seven studies were published conference abstracts.25,44,62,66,74,76,78
The diversity and number of studies make it difficult to provide
summary tables in the body of the article, and all of these data are
therefore provided as Supplementary Materials. A summary of all
study design and patient characteristics can be seen in Supplemen-
tary Appendix 4. Brief descriptions of the various SNPs detailed
below can be seen in Supplementary Appendix 2.
Global patient outcome
The relationship between various non-APOE SNPs and global/
general patient outcome is described in the subsections below. A
tabulated summary of all SNPs as they related to various measures
of global/general patient outcome can be seen in Supplementary
Appendix 5. A synthesis of these results (to the extent that was
practicable) is provided later in this section.
Neurotransmitter single-nucleotide polymorphisms. Four
studies on NTs assessed the association between various SNPs and
general patient outcome as assessed by GOS24 or GOSE,18,19,75
although the SNP analyzed, TBI severity of the cohort, and out-
come used varied between studies. The first study failed to find an
association between the catechol-O-methyltransferase (COMT)
valine (Val) to methionine (Met) SNP and GOSE at 1 or 2 years
post-injury in mainly severe TBI patients.18 The second study as-
sessed the same COMT mutation and found that Met allele carriers
(i.e., Met/Met, Met/Val, or Val/Met) displayed better GOSE at
6 months in mild TBI patients (odds ratio [OR], 2.87; 95% CI,
1.20–6.86).19 The third study evaluated the dopamine receptor D2
(DRD2)/ANKK1 SNPs, finding the ANKK1 rs1800497 heterozy-
gotes to be associated with GOS at 6 months post-injury in severe
TBI patients.24 This study failed to document any association be-
tween DRD2 SNPs and outcome. The final study again evaluated
various NT SNPs (ANKK1 rs116046/rs493801, DRD2 rs6277, and
COMT rs4680), in addition to various others.75 This study used
complex statistical modeling and found an association between all
of the above NT SNPs with patient outcome as assessed by GOSE
at 3 to 6 months post-injury.
Cytokine single-nucleotide polymorphisms. Eight studies
reported cytokine SNPs and their association with general patient
outcome across the spectrum of TBI severity.37,38,40,41,42–45 Four
studies addressed various interleukin (IL)-1 SNPs.37,38,40,41 Two of
these studies reported on the impact of IL-1A SNPs,37,38 with one
study documenting worse outcome for IL-1ra-889 allele carriers37
and the other study failing to document an association between the
SNP and outcome.38 One study documented an association between
the IL-1B-3953 SNP and poor GOS.40 Finally, the last IL-1 study
found a weak association between IL-1 receptor antagonist (IL-
1RN) SNP and worse outcomes.41
Three studies addressed the IL-6-174 SNP, with contradictory
conclusions regarding its outcome impact. One study failed
FIG. 1. PRISMA flowchart. ApoE, apolipoprotein E; SNP, single-nucleotide polymorphism; TBI, traumatic brain injury.
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to document any association between the IL-6-174 SNP and
6-month mortality.43 The remaining two studies reported signifi-
cant, but inconsistent, associations between the IL-6 polymor-
phisms and general patient outcome. One study documented better
GOS in homozygote G allele carriers,42 whereas the other study
documented better outcomes with C-allele carriers (homozygotes
or heterozygotes).44
Finally, one study assessed the tumor necrosis factor alpha
(TNFA)-308 SNP. The results of this analysis displayed worse
GOS at 6 months for the TNF-308*2+ carriers (OR, 1.63; 95% CI,
1.14–2.34).45
Brain-derived neurotrophic factor single-nucleotide poly-
morphisms. Three studies, in severe TBI patients, addressed
the association between BDNF SNPs and global patient out-
come.48,77,79 The first study failed to document any association
between BDNF rs6265 or rs71244 SNPs and mortality within the
first 7 days post-TBI. However, BNDF rs6265V homozygotes and
rs71244 T homozygotes displayed higher survival at 1 year.48
Further, Failla and colleagues48 developed a genetic risk score
(GRS) based on the presence of ‘‘risk’’ BDNF SNPs, which, when
included in a multi-variate Cox model (after adjusting for other
admission patient characteristics and complication profiles), dis-
played a positive association with survival at both 1 week and 1
year in older patients, with the opposite trend observed in younger
patients. For further details regarding this GRS and Cox modeling,
we refer the reader to the parent article.48
The second study evaluated the interactions of CSF BDNF levels
and BDNF GRS (rs6265, rs7124442) in modifying global out-
comes.79 CSF BDNF levels were associated with time until death
( p = 0.042; hazard ratio [HR] = 10.973). BDNF-GRS and serum
BDNF interactions were predictive of mortality through multi-
variate modeling ( p= 0.047; HR = 0.987).
The final study evaluated the interaction of CSF cortisol levels
with BDNF GRS (rs6265, rs7124442) in modifying global out-
come, as assessed by GOS at 6 months post-injury.77 It was found
that models including both CSF cortisol and BDNF GRS predicted
mortality in younger patients (age, <48 years; p= 0.004). This study
demonstrated some definitive links between CSF BDNF levels and
mortality, though the associated risk of mortality appeared to be
mediated by CSF cortisol, at least in part.
Mitochondrial single-nucleotide polymorphisms coding for
mitochondrial proteins. Three studies documented the associ-
ation between mitochondrial SNPs, coding for mitochondrial pro-
teins, and patient outcome.54–56 These studies included SNPs both
in mitochondrial DNA (mtDNA) and in nuclear SNPs coding for
mitochondrial proteins. The first study assessed a B-cell lymphoma
2 (BCL2) SNP and found that variant allele carriers (i.e., variant/
variant or wild-type/variant) displayed worse 3-month GOS, in
mainly mild TBI patients.56 The second study assessed various
mtDNA haplotypes, and found that haplotypes H, J, T, and U were
all associated with worse 6-month outcomes in mild-to-moderate
TBI patients.54 The last study evaluated various mtDNA SNPs as
they related to 3-, 6-, and 12-month GOS and DRS. This study
found the mtDNA 10398 G carriers to have lower DRS at 6 and 12
months post-TBI ( p< 0.02).55
Miscellaneous single-nucleotide polymorphisms. Ten
studies explored the outcome impact of miscellaneous SNPs (which
did not fit into the previously mentioned categories) across the
spectrum of TBI severity.58–61,63–65,68,70,80,81 The SNPs studied were
related to genes coding for p53,68 angiotensin-converting enzyme
(ACE),58 neuroglobulin,63 adenosine triphosphate (ATP) binding
cassette,59,61 aquaporin (AQP)-4,64 aromatase rs2470144/rs4646/
rs2470152,65 poly adenosine diphosphate-ribose polymerase-1
(PARP-1) rs3219119/rs3219090,70 mannose binding lectin-2
(MBL2)/ficolin-2 (FCN2; rs1800451, rs1800450, rs5050737,
rs7096206; rs3124953, rs17514136, rs17549193, and rs7851696),80
and calcineurin (PPP3CC; rs2443504, rs2461491, rs2469749, and
rs10108011).81
Several SNPs were found to be associated with variations in a
range of outcomes: p53 arginine homozygotes were found to have a
worse GOS at intensive care unit (ICU) discharge;68 three ACE-
related SNPs (C minor allele carriers for rs4461142, C minor allele
carriers for rs7221780, and T minor allele carriers for rs8066276)58
were associated with worse 6-month GOS; neuroglobulin rs3783988
C allele carriers were associated with poor GOS at 3/6/12/24
months63; ATP binding cassette C3435T C allele carriers were as-
sociated with worse 6-month GOS61; AQP-4 rs3763043 T homo-
zygotes were associated with worse GOS at 6 months64; aromatase
rs2470144A allele carriers were associated with worse outcome at 6
months;65 PARP-1 rs3219090A allele/rs3219119 T allele carriers
were associated with poor GOS at 6 months70; and calcineurin
PPP3CC rs2443504 AA carriers had increased risk of mortality at 12
months.81 Finally, no association with global outcome was observed
for SNPs in MBL2 or FCN2.80
‘‘Other’’ outcomes: Neuropsychiatric, behavioral,
miscellaneous
Themultiple studies that contributed to this section of the review
were varied in terms of SNPs addressed, the endpoints used, and the
sample sizes in individual studies. The following description of the
results of the review reflects this heterogeneity, which makes
summary difficult; we have therefore classified these primarily by
the target group in which the SNPs occurred.
Neurotransmitter single-nucleotide polymorphisms. Twenty-
one studies documented the association between SNPs in a range
of NT genes and neuropsychiatric/behavioral outcome post-
TBI.16,17,19–36,74 The full spectrum of TBI severity was described in
the included studies. The NT based SNPs described included:
ANKK1 TAQ1a,74 COMT,16,17,19,20 monoamine oxidase type A
(MAO-A),21 DRD2/ANKK1,22–28 vesicular monoamine trans-
porter type 2 (VMAT2),29 combination of monoamine SNPs
(COMT/DRD2/ANKK1/VMAT),30 5-HTTLPR,31,32 glutamic acid
decarboxylase (GAD),33 vesicular glutamate transporter type 1
(VGLUT1),34 and GRIN2A.35,36 Full details of various neuropsy-
chiatric and behavioral outcomes related to SNPs in NT genes can be
seen in Supplementary Appendix 6.
Four studies focused on COMT SNPs and their association with
neuropsychiatric/behavioral outcome.16,17,19,20 The mutation
evaluated in every study was the Val-158-Met SNP. Conflicting
results were observed regarding the impact of this polymorphism
on outcome. One study documented Val/Val homozygotes to have
worse perseverance post-TBI,16 a second (in contrast) reported
worse post-traumatic behavior and cognition in Met allele carri-
ers,17 whereas a third study documented no difference in attention/
cognitive performance on both univariate and multi-variate re-
gression.18 Finally, a fourth study documented improved nonverbal
processing skills in Met allele carriers.20
Eight studies documented the association between various
DRD2/ANKK1 SNPs and neuropsychiatric/behavioral outcomes.
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The DRD2 SNPs and the linked behavioral effects were: rs686A
allele carriers had less aggression,22 C95T T allele carriers were
found to have improved California Verbal Learning Test -II
(CVLT-II) scores at 6 months,23 and the rs2724838 SNP was asso-
ciated with worse depression at 12 month post-injury.24 In addition,
DRD2 rs6279 C-homozygotes displayed improved cognition at
6 months; and executive function ( p= 0.013), attention ( p= 0.006),
and language fluency at 6 months ( p= 0.003).24 Similarly, the
ANKK1 SNPs and associated outcomes were: ANKK1 A2 allele
carriers had worse depression and behavioral issues,17 ANKK1
rs1800497 homozygotes had worse cognition17,74 and executive
functioning at 6 months post injury ( p= 0.048),24 and ANKK1/
TAQ1A T allele carriers were found to have worse CVLT scores in
four studies.25–28
Mutations in VMAT2 were documented in two studies.29,30 The
first study found the rs363226 SNP to be associated with worse
cognition at 6 months post-injury ( p = 0.006).29 The second study
evaluated a panel of monoamine-based SNPs (COMT/DRD2/
ANKK1/VMAT), finding independent associations between:
ANKK1 rs1800497, COMT rs4680, DRD2 rs6279, and VMAT
rs363226 with cognition at 6 months post-injury.30
Polymorphisms in the serotonin transporter gene were assessed
in two studies; both failed to demonstrate a statistically significant
association between these SNPs of the 5-HTTLPR region and de-
pression post-TBI.31,32
Finally, SNPs related to glutamate neurotransmission were
evaluated in three studies.34–36 One study addressed polymor-
phisms associated with the VGLUT1 gene, and found that G allele
carriers had longer recovery times post-concussion.24 Two studies
addressed SNPs in the GRIN2A gene associated with N-methyl D-
aspartate receptor subunits.35,36 One study found L homozygotes to
have a 6 times increased chance of prolonged recovery from their
concussive symptoms ( p= 0.043).35 The second study documented
the rs968301 GRIN2A SNP to be associated with a statistically
significant decrease in intelligence post-TBI ( p= 0.025).
Cytokine single-nucleotide polymorphisms. Two studies
documented the association between cytokine based SNPs and
‘‘other’’ patient outcomes.39,41 One study assessed SNPs in the IL-
1B gene and found the rs1143634 CT genotype to be associated
with post-traumatic epilepsy (PTE; OR, 2.85; p = 0.005).39 The
second study assessed the IL-1RN*2 SNP and found that the car-
riers displayed increased risks of poor outcomes (OR, 0.375; 95%
CI, 0.155–0.901; p = 0.028) and hemorrhagic events.41 Full details
on these studies and the outcomes studied can be observed in
Supplementary Appendix 7.
Brain-derived neurotrophic factor single-nucleotide
polymorphisms. Nine studies documented the association be-
tween BDNF-based SNPs and neuropsychiatric/behavioral out-
comes.46,47,49–53,76,78 Six studies evaluated the BDNF Val-66-Met
SNP as it related to these various outcomes.46,47,49–52,76,78 One
study assessed the relation of BDNF SNPs at rs71 24442 to
cognitive outcome.53 Full details can be seen in Supplementary
Appendix 8.
BDNF Val-66-Met SNPs displayed varied and inconsistent ef-
fects across the studies identified. The BDNF Val-66-Met SNP was
found to have the following documented associations post-TBI:
Met allele carriers showed improved Wechsler Adult Intelligence
Scale (WAIS) scores ( p < 0.01),46 Met allele carriers displayed
improved executive functioning,49 Met allele carriers had reduced
treatment response to citalopram for depression post-TBI,50 and
Met allele carriers had both worse reaction times ( p = 0.0003)51 and
memory ( p = 0.05) at 6 months post-TBI.52 Further, one study
found Met carriers were also found to have worse capacity in all
domains of neurocognitive functioning, except visuospatial.77,79
Finally, one study failed to document any difference in BDNF Val-
66-Met SNP status and emergence from vegetative state at 3, 6, or
12 months post-injury.47
One study evaluated various SNPs of the BDNF gene, finding
the rs7124442 CC homozygotes to display the largest decline in
intelligence (as assessed by intelligence quotient [IQ]).53
Miscellaneous single-nucleotide polymorphisms. Ten
studies documented the relationship between various SNPs and
nonglobal patient outcomes (i.e., neuropsychiatric, behavioral, and
other).57,60,66,67,69,71–73,82,83 The targets for these polymorphisms
included: ACE,57 various oxytocin SNPs,66 PERIOD3,67 ATP
binding cassette,60 nitric oxide synthase-3 (NOS3),69 alpha synuclein
(SNCA),71 kidney and brain expressed protein (KIBRA),72 BMX,73
methyenetetrahydrofolate reductase (MTHFR),82 and adenosine A1
receptor.83 Full details can be found in Supplementary Appendix 9.
A full explanation of all abbreviations used in the other appendices
can be found in Supplementary Appendix 10.
Synthesis of data
The substantial variation that we encountered in study design,
outcome metrics and timing, and SNPs targeted made it impossible
to undertake a meta-analysis of these data. The details of individual
studies are provided in the Supplementary Material that has been
cited throughout the Results section. However, Table 1 provides a
summary of those studies that examined the impact of target
polymorphisms on global outcome. Similarly, whereas Appendix 2
in the Supplementary Materials provides a brief description of
background biology, Figure 2 provides a more accessible summary
of the cellular and subcellular location of the different genetic
targets addressed by these candidate gene studies, in order to pro-
vide a pathophysiological context for the processes that these
polymorphisms might be influencing.
Risk of bias
In general, risk of bias was variable in all domains for most
studies. Given the observational nature of all studies, methodo-
logical weaknesses were frequent. These most commonly involved
failure to address potential confounders in patient selection or
analysis, and selective outcome reporting. Only one of the 68 as-
sociation analyses that we reviewed had low risk of bias in all of the
areas assessed, and 14 studies had one or more fields within the
QuIPS assessment graded as ‘‘high’’ risk of bias, with this most
commonly attributed to either study attrition or issues surrounding
confounding. A tabulated summary of the QuIPS grading can be
seen in Supplementary Appendix 11.
Discussion
This review summarizes the current literature on the impact of
SNPs in non-APOE genes on patient outcomes post-TBI. In-
tegrating these results is a complex task because of the diversity of
biology addressed in these articles. Further, the scientific and
clinical inferences that can be drawn from these data are limited by
the small sample sizes in most studies, biases identified, and lack of
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uniformity in reporting populations and outcomes. The following
discussion provides an overview of our findings, and subsequently
explores the reliability and relevance of any inferences that emerge
from our analysis.
First, many studies have explored the impact of SNPs in
neurotransmitter-related genes. The majority of these focused on
genetic variations associated with various aspects of monoamine NT
metabolism and transport,16–36,74,75 with COMT/DRD2/ANKK1
mutations being the most commonly reported, and the majority of
outcomes focused on neuropsychiatric and behavioral assessments.
Given that monoamine NT are believed to play significant roles in a
variety of neuropsychiatric and neurodegenerative conditions, it is
unsurprising that these NTs may be involved in psychiatric, behav-
ioral, and cognitive sequelae of TBI.84 The current literature is based
on small patient numbers and provides conflicting evidence for these
SNPs.
Second, cytokine-related SNPs represent a small proportion
of the available literature, with only nine studies that have as-
sessed an association with patient outcomes.37–45 The poly-
morphisms addressed in these studies included the following
cytokines: IL-1a, IL-1b, IL-1RN, IL-6, and TNFA, with most
studies documenting the association between these SNPs and
global patient outcome. Given the documented association be-
tween serum,85 cerebrospinal fluid,86 and cerebral microdialysis87
cytokine profiles and patient outcome, the relationship between
various cytokine SNPs and outcome is a logical extension.
Changes in cytokine expression, and thus inflammatory response,
in TBI represents a plausible mechanism by which such SNPs
could affect outcomes in TBI.
Third, BDNF-related studies mainly focused on neuropsychiatric/
neurobehavioral outcomes associated with various SNPs.46–53,76–79
Given that BDNF is involved in neuronal survival and axonal
signaling/regeneration post-injury, the potential role of various
BDNF SNPs is interesting.88 Varying mutations in the genes that
encode BDNF could modulate the pathophysiology of neuronal/
axonal injury and repair, and hence affect the incidence and se-
verity of late cognitive, psychological, and psychiatric sequelae.
This mechanistic framework explains the results of several studies,
FIG. 2. Diagrammatic representation of tissue, cellular, and subcellular location of non-APOE target in candidate gene studies. The
box at top right depicts a variety of neurochemical synapses and locates the target gene products in pre-synaptic sites, post-synaptic
sites, or synaptic cleft. The vessel at bottom left shows interactions with astrocytes, microglia, and egressing neutrophils and
lymphocytes. The star-bursts represent sites of inflammatory injury. A = astrocyte, ADP = adenosine diphosphate, ATP = adenosine
triphosphate, GABA = gamma aminobutyric acid, M =microglia, MBL =mannose binding lectin, mt =mitochondria, N = neuron,
O2 = oxygen, S = synapse, and SNP = single-nucleotide polymorphism. Diagram depicts a theoretical framework for the interaction of
various SNPs identified within the review. Diagram depicts neuronal, microglial, astrocytic, synaptic, endothelial, leukocyte, mi-
tochondrial, nuclear, and cytosolic areas impacted by various SNPs. *Note: SNPs that are italicized could not be slotted into the
diagram, but are listed secondary to their identification within the systematic review. APOE, apolipoprotein E.
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which show that various neuropsychiatric/behavioral tests were
related to BDNF SNP status.
Fourth, mitochondrial polymorphisms were assessed in only
three studies.54–56 All of these documented associations between
variousmitochondrial mutations and global patient outcome at 6–12
months post-injury. These findings are not unexpected, given that
mitochondrial function is crucial in maintenance of metabolism and
intracellular homeostasis.89 However, with only three studies to date
assessing mitochondrial SNPs or haplotypes, it is difficult to con-
clusively define the role of these SNPs on patient outcome.
Fifth, other individual SNPs were described in relation to a range
of patient outcomes. Whereas these did not group into any of the
SNP categories described above, it appears that these SNPs tend to
populate some interesting potential ‘‘functional clusters’’ of genes.
First, a cluster of SNPs related to neurovascular and blood–brain
barrier (BBB) function were described. These included: ACE,57,58
ATP binding cassette,59–61 NOS, and AQP.64 The ACE and NOS
SNPs may play a role in vascular caliber and pre-capillary regu-
lation of cerebral blood flow, whereas the ATP binding cassette
protein and AQP are involved in solute transport59 and water ho-
meostasis64 across the BBB. These functional links provides a
framework through which genetic variation in the function of these
proteins could impact survival and neuropsychiatric/behavioral
function post-TBI.
A second class of SNPs involved neuroprotective/regulatory
proteins: p53,68 calcineurin,62,83 neuroglobin,63 aromatase,65 and
PARP.70 All of these have recognized functions in central nervous
system function, injury, and repair. p53 is involved in cell-cycle
regulation,90 whereas calcineurin is involved in immune regula-
tion.91 Aromatase regulates sex steroid hormone levels, and could
modulate the tissue effects of estradiol, which is believed to
possess neuroprotective properties.92 Neuroglobin is believed to
be protective in states of hypoxia,93 whereas PARP is believed
involved in the regulation of energy stores.94 Altered function
within these domains of regulation/neuroprotection could be ex-
pected to impact global and neuropsychiatric/behavioral outcome
post-TBI.
Finally, the last cluster of miscellaneous SNPs were those
specific to neuropsychiatric/degenerative states. These SNPs were
related to: KIBRA72 (involved in hippocampal functioning),
PERIOD67 (involved in circadian rhythm functionality), and
SNCA71 (known to play a function in synucleopathic degenera-
tive processes). These proteins are believed to have effects in
neuropsychiatric, sleep, and neurodegenerative conditions and
could be expected to modulate psychiatric and behavioral out-
come post-TBI.
Despite these interesting ‘‘clusters’’ of SNPs within the mis-
cellaneous group of the review, the number of studies in these
clusters were small with only preliminary results described.
It is worth noting that the vast majority of SNPs identified in
association studies occur in noncoding regions of the genome,
where their effect on phenotype cannot be explained by a direct
effect on protein translation as is the case in common Mende-
lian diseases. The effects of these noncoding alleles is through
more subtle mechanisms involving regulation of gene expression
through multiple mechanisms involving RNA splicing, tran-
scription factor binding, DNA methylation, and microRNA re-
cruitment.95 For a minority of the polymorphisms listed above,
such allele differences have been associated with the expression
of cognate proteins in humans. Failla and colleagues studied
BDNF in patients with TBI and explored the effect of the rs6265
Met-allele and rs7124442 C-allele, both of which have been as-
sociated with reduced BDNF signaling.48,79 They found that
genetic variance in BDNF demonstrated interactions with both age
and serum BDNF levels in predicting outcome. Diamond and col-
leagues examined polymorphisms in the IL-1b gene in TBI, and
displayed that the rs1143634 CT allele was associated with lower
serum IL-1b, higher CSF/serum IL-1b ratios, and an increased risk of
post-traumatic epilepsy,39 whereas other studies have linked differ-
ent SNPs to the development of post-traumatic epilepsy.33,82,83,96
These narratives tie genetic polymorphisms into outcome effects
through clear mechanistic effects. However, many polymorphisms
that are associatedwith outcome in this context have not been studied
for a mechanistic link in humans
Limitations
The studies reviewed in this article address the impact of SNPs in
genes other than APOE, and many provide evidence of association
between cognate SNPs and outcome in TBI. The functional roles of
these proteins, and their demonstrated role in non-TBI diseases,
provides a plausible framework through which they might impact
outcome in TBI. However, despite these interesting results, im-
portant limitations need to be highlighted.
First, given that our systematic review was conducted on all
non-APOE SNPs in all degrees of TBI severity, the overall re-
sults are difficult to synthesize into a single unifying conceptual
scheme. Further, the number of patients included in each indi-
vidual study varied, with most studies reporting on fewer than
200 patients. The poor statistical power inherent in these small
sample sizes not only reduces the confidence in the effect sizes
reported, but is also likely to bias toward the finding of positive
results.97 This lack of statistical power is further compounded by
(the often unrecognized) multiple testing in some patient popu-
lations, and may also account for some studies that showed no
association between studied SNPs and outcome. Conversely, it is
likely that many small negative studies simply did not reach
publication, and the resulting publication bias means that our
summary of the published literature may not accurately represent
the research undertaken in this context.
Second, many of these studies originated from centers with a
particular focus in this research area, with many articles studying
different SNPs on the overlapping patient cohorts. Consequently,
despite interesting results described in these articles, it may be
difficult to generalize these findings to other regions within the
world where certain genetic patterns may not be present or similarly
represented within their populations.
Third, we purposefully avoided including studies looking at
APOE genotype and outcomes in adult TBI. Thus, at the current
time, we cannot make direct comments regarding the association,
or added predictive power over existing models, of APOE geno-
typing on patient outcome in adult TBI. Given the comprehensive
literature body on APOE in adult TBI, our group decided to exclude
this from the above living systematic review on non-APOE SNPs to
avoid a hasty overview of APOE in an already large overview of
TBI genetics. We are currently in the process of completing a
separate and distinct living systematic review on APOE in adult
TBI, which will address the potential added benefit in outcome
modeling.
Fourth, many studies failed to account for various confounding
factors known to impact outcome in TBI. In particular, many failed
to adequately account for injury severity at presentation, using one
of the well-recognized risk adjustment schemes such as IM-
PACT.1,3 The absence of such risk adjustment makes it difficult to
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parse out nongenetic drivers of outcome variation and more spe-
cifically study the effect of genetic variation on TBI outcome.
Secondary brain injury events and disease course can also modify
outcome significantly (especially in more severe TBI), and the
absence of characterization of such events does not allow us to
correct for such covariates, or indeed use them as intermediate
outcomes in mediation analyses.98 Similarly, the neuropsychiatric/
neurocognitive assessment tools implemented varied significantly
between studies. This limits our ability to treat similar outcomes,
such as depression, as common phenotypic endpoints for meta-
analysis across studies. Finally, given the significant heterogeneity
between studies, including those addressing the same SNP, wewere
unable to conduct a meta-analysis.
Fifth, we chose to use the QuIPS tool to assess bias in the studies
we reviewed, as a more specific tool for a study of the prognostic
impact of genotype on outcome, rather than other risk of bias as-
sessment tools, such as the RTI Item Bank99 (designed to assess
bias and precision in observational studies), the Cochrane Risk of
Bias tool100 for intervention studies, and the QUADAS-2 (Quality
Assessment of Diagnostic Accuracy Studies) tool101 for diagnostic
studies. When assessed against QuIPS, all but one of the 68 asso-
ciations reviewed had at least moderate risk of bias in one or more
of the QuIPS categories, and 14 had a high risk of bias in one or
more categories.
Sixth, whereas we did seek data on age and gender in our ab-
straction of studies, the results in these studies, with few exceptions,
did not account for the impact of these variables on genetic asso-
ciations. In any case, studies were rarely powered adequately to
undertake such an analysis. We also considered exploring the im-
pact of ethnic variance on associations, but discarded this option,
because an initial assessment of the literature showed that these
data were largely unavailable. This is an important omission, given
that ethnic background is clearly a likely driver of differences in
this context.102
It is worth emphasizing that our inclusion/exclusion criteria
were strict in that studies with less than 5 patients were excluded.
Although this sample size threshold would be very small for genetic
association studies, we selected this because we wished to be as
inclusive as possible in finding relevant data that might contribute to
a potential meta-analysis. In the event, study heterogeneity made
such a meta-analysis impossible. However, even with this low
threshold, studies highlighting individual case reports or small case
series on interesting SNPs as they relate to patient outcomes were
not included or discussed in this review, even if they had suggested
potential to impact outcome. An example of this would bemutations
in the voltage gated calcium channel—CACNA1A—which have
been shown to be related to epilepsy and disease-related edema in
many studies,103,104 and associated with cerebral edema after mild
TBI.105 This mutation, and potentially others, may prove important
as future larger, prospective studies provide additional information.
Seventh, this living systematic review only focused on non-
APOE polymorphisms and their association with clinically relevant
outcomes in adult TBI. Thus, comments on the link between var-
ious SNPs and post-mortem histological changes cannot be made
within this review. The scope of the systematic review was large in
any case, and we needed to restrict the field to make it manageable,
and this was one of the a priori restrictions set in the literature
search. We elected not to include post-mortem findings because it
would have required consideration of an entirely new set of out-
comes (pathological and histological findings), which would have
taken up a great deal of space in an already long article. Whereas all
of the studies we encountered for this living systematic review were
based on convenience samples, this is particularly the case in post-
mortem studies, and though these provide clear insights into TBI
biology, defining their quantitative relationship to the wider TBI
population is not easy. Thus, a main limitation of this living sys-
tematic review is that this link with histological outcomes was not
explored, though we acknowledge that this is something of im-
portance and deserves attention during future renditions of this
living systematic review.
Finally, the results of the studies in this review speak broadly to
the role of host response in modifying disease course and outcome
in TBI. It is highly unlikely that any individual gene functions in
isolation in this context, and most of the networks that we discuss
represent the interaction of several proteins. Consequently, in ad-
dition to examining the impact of individual genes on outcome, it
may also be important to find ways of identifying the integrated
impact of networks of genes that affect common pathways.106
Table 1 provides an overview of the various SNPs and their impact
on global outcomes measures in TBI.
Such a detailed exploration and synthesis of how polymorphisms
in individual genes result in an integrated effect on outcome is
beyond the scope of this review. However, it is possible to draw
some broad conclusions about the mechanisms of outcome impact
of the genetic variation discussed in this review (see Fig. 1). Ge-
netic variation could affect TBI outcome by modulating critical
components of injury response, vascular biology, or inflammation
cascades, affecting molecules that govern repair and recovery (such
as BDNF), or result in differences in pre-injury traits (such as re-
silience or cognition), with such ‘‘adverse alleles’’ only be ex-
pressed if cognitive reserve is challenged by injury. For example,
polymorphisms in ANKK1 may modulate response latency after
mild TBI and poorer performance on the CVLT-II and nonverbal
processing speed.
The limitations that we discuss above may also, to some extent,
account for some of the interstudy inconsistencies that we ob-
served, given that variations in injury severity, timing of outcome
assessment, and assessment tools used could result in legitimate,
but varying inferences in analyses that address the impact of a given
polymorphism.
Considerations for future studies in adult traumatic
brain injury
It is important to point out that any genetic study, regardless of
whether it addresses candidate genes or uses a GWAS approach,
needs to take account of the fundamentals of good genetic epide-
miology. A detailed discussion is beyond the scope of this article
(readers are referred to some excellent reviews107–110), but a few
points are worth highlighting. For example, the results fromGWAS
studies are increasingly only perceived to be robust when the results
in a Stage 1 (or Discovery) cohort are replicated in a Stage 2 (or
Replication) cohort. Most current GWAS studies will address
several hundred thousand (typically 500,000–1,000,000) SNPs.
The risks from multiple comparison penalizes any statistical sig-
nificance that is observed, meaning that in Discovery cohorts, for
example, p values <5 · 10–8 need to be achieved to demonstrate
robust effects. This, in turn, mandates large sample sizes (see be-
low). Several other confounders in such studies (e.g., such as racial
differences in allelic frequency) are mentioned above, in the
Limitations section.
Notwithstanding these limitations in the literature that we re-
viewed, we believe that the genetic variations explored in these
studies have a plausible role in affecting outcome after TBI. If
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confirmed, the insights obtained could be used to refine outcome
prediction models, identify new therapeutic targets, and potentially
stratify patients for precision medicine approaches with new
agents. However, addressing these aspirations requires both addi-
tional studies and new approaches to analysis. There is a strong case
to move from candidate gene studies to genome wide association
studies (GWAS) in order to obtain a more complete, unbiased, and
integrated understanding of the effect of genetic variation on dis-
ease course and outcome in TBI. GWAS studies exploring the
impact of genotype on outcome are relatively uncommon, given
that most such studies compare cases and controls to determine the
impact of genetic variation on disease incidence, rather than out-
come. However, the principles used in case control studies111 can
be extended to outcome studies, and application of these principles
suggest that sample sizes required to reach the conventional
p < 5 · 10–8 threshold will depend on various factors. The first of
these is the frequency of the outcome of interest. Data from a
20,000-patient trial112 suggest that we should expect unfavorable
outcome rates of around 45% in moderate-to-severe TBI and
around 30% across the entire TBI severity range. Other factors
include the risk allele frequency (which ranges from 0.05 to 0.5)
and the effect size of possessing this risk allele.
Data from the papers examined in this review suggest a wide
range of effect sizes, but past experience from other diseases sug-
gests that likely effect sizes for the impact of genetic variation on
outcome in complex diseases are likely to show ORs in the range of
1.2–1.5. Given the heterogeneity in TBI at presentation, these ef-
fects are unlikely to be demonstrable in sample sizes less than
2000–4000 patients in a single severity category (assuming, e.g.,
45% unfavorable outcomes in moderate-to-severe TBI), and ro-
bustly powered studies to detect small effect sizes may require
sample sizes of about 10,000 (see Fig. 3). Simulations were done
using simple logistic regression under additive genetic association
assumption. The range of effect sizes reflect typical ORs observed
in first rounds of genetic association studies for complex diseases,
such as in the original Wellcome Trust Case-Control Consortium
study (WTCCC).113 With *50% more cases (unfavorable out-
come) and*100% more controls (favorable outcome) than in the
original WTCCC study, the figure illustrates that studies of this size
should be well powered in this target OR range). The power of these
samples to detect associations is not uniform, but will vary de-
pending on the outcome being interrogated. Such studies are only
possible through international collaborative efforts. Further, even
with such large sample sizes, the parsing of genetic effects on
outcome will require that we account for other covariates that
modulate outcome, characterized (as a minimum) by recording the
variables that contribute to common risk adjustment schemes such
as IMPACT.1,3 More detailed stratification of samples (e.g., by age
and sex) or the need to account in a more detailed fashion for
preinjury comorbidities (e.g., depression) will make greater de-
mands on sample size, but could provide greater robustness and/or
refinement of inferences regarding genotype-phenotype associa-
tions. With the hope of the widespread adoption of GWAS tech-
niques, outlined above, future renditions of this living systematic
review on non-APOE SNPs in adult TBI will be able to apply meta-
analytic techniques, providing powered statistical support for the
associations outlined in the current version of this review.
Conclusion
Although the size and quality of past studies prevent rigorous
inferences, the available data are consistent with the scientifically
plausible conclusion that various NT-, cytokine-, and BDNF-based
SNPs may be associated with patient global outcome at 6–12
months post-TBI. The association between NT, cytokine, and BDNF
SNPs with neuropsychiatric and behavioral outcomes at 6–12
months post-TBI is less clear, with conflicting results for similar
SNPs across various studies. These results suggest an important role
for variations in host response in modulating disease course and
outcome post-TBI. However, definitive conclusions in this regard
will require adequately powered and better designed GWAS studies,
which account for nongenetic covariates that drive outcome, and
examine the role of network function in TBI. Such studies are un-
derway and will yield new data over the next few years. This living
systematic review will be revised and updated as new evidence be-
comes available from these and other studies.
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